(Q52852639)

English

Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis.

scientific article published on 26 February 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Silvan Vesenbeckh

1

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

David Krieger

2

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Gudrun Bettermann

3

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Nicolas Schönfeld

4

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Torsten Thomas Bauer

5

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Holger Rüssmann

6

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Harald Mauch

7

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

publication date

26 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

98

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

27-29

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Improving the health of the tuberculosis drug pipeline

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Chlorpromazine: A Drug Potentially Useful for Treating Mycobacterial Infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2016.02.003

7 January 2021

Identifiers

10.1016/J.TUBE.2016.02.003

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 May 2018

http://europepmc.org/abstract/MED/27156615

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52852639&oldid=2132064730"